Cargando…
Tryptophan 2,3-dioxygenase may be a potential prognostic biomarker and immunotherapy target in cancer: A meta-analysis and bioinformatics analysis
BACKGROUND: Tryptophan 2,3-dioxygenase (TDO2) is one of the emerging immune checkpoints. Meanwhile, TDO2 is also a key enzyme in the tryptophan (Trp)–kynurenine (Kyn) signaling pathway. Many studies have evaluated that TDO2 is highly expressed in various malignant tumor patients and plays a prognost...
Autores principales: | Hu, Yanyan, Liu, Zhongjian, Tang, Hui |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9574363/ https://www.ncbi.nlm.nih.gov/pubmed/36263228 http://dx.doi.org/10.3389/fonc.2022.977640 |
Ejemplares similares
-
Editorial: Targeting Indoleamine 2,3-dioxygenases and Tryptophan Dioxygenase for Cancer Immunotherapy
por: Brochez, Lieve, et al.
Publicado: (2021) -
FOXP4-AS1 May be a Potential Prognostic Biomarker in Human Cancers: A Meta−Analysis and Bioinformatics Analysis
por: Zhang, Guangming, et al.
Publicado: (2022) -
Exploring the mechanism of tryptophan 2,3-dioxygenase
por: Thackray, Sarah J., et al.
Publicado: (2008) -
Prognostic role of indoleamine 2,3-dioxygenase 1 expression in solid tumors: A systematic review and meta-analysis
por: Zhang, Haiyan, et al.
Publicado: (2022) -
Targeting Indoleamine Dioxygenase and Tryptophan Dioxygenase in Cancer Immunotherapy: Clinical Progress and Challenges
por: Peng, Xuerun, et al.
Publicado: (2022)